OUR TEAM

Board of Directors

Keith R Carlton

Chief Executive Officer

In addition to holding the CEO role for EBT, Mr. Carlton is also a Co-Founder and General Partner at Guide Medical Ventures, a seed investment and management consulting firm.

Greg Madden

Partner focused on medical device and healthcare services

Mr. Madden is a partner at SV Health with over 18 years of healthcare transaction experience, including deep private and public healthcare company investment experience

Jeff B Smith

Co-Founder & Managing Partner, Ignite Venture Studio

Jeff is a seasoned Fortune 50 CPG leader-turned-entrepreneur.

Jamie Stiff

Partner and Managing Director

Mr. Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007 and Managing Director in 2016.

Paul Yoo, PhD

Co-Founder, President, and Chief Scientific Officer

Professor Yoo’s research spans diverse areas of peripheral nerve stimulation therapies, such as neural control of lower urinary function, obstructive sleep apnea, and chronic heart failure.

Sasha John, PhD

Observer

Dr. John is a serial entrepreneur and inventor, with over 25 years of R&D in algorithm-based neurostimulation and assessment of brain and heart data.

0

Keith R Carlton

Chief Executive Officer

In addition to holding the CEO role for EBT, Mr. Carlton is also a Co-Founder and General Partner at Guide Medical Ventures, a seed investment and management consulting firm. Prior to EBT, Mr. Carlton was President & CEO of HUINNO, Inc., a digital healthcare platform company focused on improving the management and costs of hypertension through wearables and software. Prior to HUINNO, Mr. Carlton held multiple positions at Boston Scientific Neuromodulation including Director of New Therapy Development (focused on Pain, Deep Brain Stimulation, Overactive Bladder, and other areas). Mr. Carlton joined Boston Scientific through the acquisition of Intelect Medical where he was Co-Founder and VP of Product Development. Prior to founding Intelect, Mr. Carlton also held various roles at Medtronic where he was co-inventor of the InterStim tined lead and developed InterStim II for OAB. He also served as Director of Engineering at Texcel Medical (now Cirtec Medical). Mr. Carlton holds over 40 patents around electrical stimulation products and therapies. He has dual B.S. degrees in Biomedical Engineering and Engineering Mechanics from The Johns Hopkins University and an MBA from Boston University.

Greg Madden

Partner focused on medical device and healthcare services

Mr. Madden is a partner at SV Health with over 18 years of healthcare transaction experience, including deep private and public healthcare company investment experience. He joined SV in 2002 as an Analyst and later transitioned to the role of Portfolio Manager with both portfolio and lead fundraising responsibilities. Following business school, Greg was promoted to Principal and became Partner in 2018. Greg is focused on medical device and healthcare services investments and is actively engaged in the financing, strategy, operations and acquisitions of portfolio companies. His active investments include AcuFocus, BardyDx, CardioFocus, CSA Medical, Endotronix, Leiters, Solsys Medical (now Misonix (NASDAQ: MSON), Stimwave, and Ximedica. Prior to SV, Greg worked at Testa, Hurwitz & Thibeault, in the Business Practice, Emerging Technology and Private Equity groups, supporting both venture capital funds and venture backed companies in business formations and financings, mergers and acquisitions, and venture capital fundraising. He holds a BA (with honors) from Colby College, and an MBA from Boston University (Beta Gamma Sigma).

Jeff B Smith

Co-Founder & Managing Partner, Ignite Venture Studio

Jeff is a seasoned Fortune 50 CPG leader-turned-entrepreneur.  For a majority of Jeff’s career he served in various senior leadership roles at Johnson & Johnson, the world’s largest and most diversified healthcare company. Most recently, he served as Company Group Chairman, North America and oversaw several divisions and brands including Tylenol®, Zyrtec®, Band-Aid Brand®, and Neutrogena®. During his time at J&J, he developed a strong track record of building and marketing global brands, driving insight-driven innovations, leading strategic business turnarounds, and delivering profitable growth. Retiring from J&J, Jeff co-founded and is Managing Partner of Ignite Venture Studio, which develops brands to disrupt the ‘startup-quo’ by building and accelerating their performance to achieve success in collaboration with strategic partners. Jeff recently launched Paragon Vitamins, a subscription service personalized through metabolic testing, and Fluent Health, an integrated direct-to-patient solution for influenza and the common cold.

Jamie Stiff

Partner and Managing Director

Mr. Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in nine early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Past board affiliations include Allostera Pharma Inc., gIcare Pharma Inc., Interface Biologics, Inc., Matregen Corp, Naurex Inc. (acquired by Allergan NYSE:AGN), NeurAxon Inc., StemPath Inc., Therapeutic Monitoring Systems Inc., and Zelos Therapeutics Inc. Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.

Paul Yoo, PhD

Co-Founder, President, and Chief Scientific Officer

Professor Yoo’s research spans diverse areas of peripheral nerve stimulation therapies, such as neural control of lower urinary function, obstructive sleep apnea, and chronic heart failure. In addition to academic research, Dr. Yoo has worked on various projects with medical technology companies, such as Imthera Medical Inc, Microtransponder Inc., Ethicon Endosurgery, Boston Scientific Corporation, and Nuviant Medical. Prior to joining the University of Toronto in 2012, Dr. Yoo worked both as a post-doctoral research associate and assistant research professor at Duke University under Warren Grill. Dr. Yoo received his B.A.Sc from the University of Toronto in Engineering Science (Biomedical Option), M.S. in Biomedical Engineering from the University of Southern California, and Ph.D. from Case Western Reserve University in Biomedical Engineering.

Sasha John, PhD

Co-Founder and Chief Innovation Officer

Dr. John is a serial entrepreneur and inventor, with over 25 years of R&D in algorithm-based neurostimulation and assessment of brain and heart data. He is the sole inventor on the first patents for statistical closed-loop neurostimulation which were licensed into Neuropace’s FDA approved treatment for epilepsy. He is a co-inventor of an EEG-based hearing assessment technology acquired by Bio-logic Systems Corp which became the company’s best-selling product before its acquisition by Natus. He holds 85+ patents and has been an IP strategy consultant for industry in the areas of neurostimulation, neurodiagnostics, wireless power transmission, and renal nerve ablation. As Chief Scientific Officer for AngelMed he helped obtain FDA approval of the world’s first implantable heart-attack detector and has led publication, clinical trial design, and market access strategies. He has lectured on medical commercialization at the IBBME (University of Toronto) since 2007. Sasha holds an MSc in Psychiatry (McGill) and a PhD in Medical Science (University of Toronto).